Insider Buying: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Purchases $37,812.18 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par bought 4,137 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was acquired at an average cost of $9.14 per share, for a total transaction of $37,812.18. Following the completion of the purchase, the insider now directly owns 5,090,582 shares of the company’s stock, valued at $46,527,919.48. The trade was a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, February 7th, Venrock Healthcare Capital Par bought 73,649 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average cost of $9.29 per share, for a total transaction of $684,199.21.
• On Monday, February 3rd, Venrock Healthcare Capital Par bought 14,562 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average cost of $9.22 per share, for a total transaction of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average cost of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Stock Up 2.1 %

Shares of KALV opened at $9.53 on Friday. The business’s 50 day moving average price is $8.75 and its 200-day moving average price is $10.57. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $16.88. The stock has a market cap of $470.97 million, a P/E ratio of -2.62 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. On average, equities analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. JMP Securities initiated coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective on the stock. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, KalVista Pharmaceuticals has an average rating of “Buy” and an average target price of $23.80.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC boosted its position in shares of KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 1,319 shares in the last quarter. HighVista Strategies LLC raised its holdings in KalVista Pharmaceuticals by 4.5% in the 3rd quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock worth $386,000 after acquiring an additional 1,432 shares during the last quarter. Legal & General Group Plc raised its holdings in KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 1,494 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in KalVista Pharmaceuticals by 8.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock worth $262,000 after acquiring an additional 1,670 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in KalVista Pharmaceuticals by 24.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after acquiring an additional 2,043 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).